The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
When we get delisted on AIM,shares will be transfered to the US. I believe they will be worth more there.
Medgenics, Inc. Announces Proposed Cancellation of Admission to Trading on AIM Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that it has filed preliminary proxy materials with the U.S. Securities and Exchange Commission (SEC) in connection with the Company's Annual Meeting of Stockholders on 8 April 2014, which, among other proposals, seeks stockholder approval for the cancellation of the admission of its common stock for trading on the London Stock Exchange's Alternative Investment Market (AIM). If stockholders approve the cancellation of admission to trading on AIM, it is anticipated that the last day of trading on AIM will be 15 April 2014, and the effective date of cancellation will be 16 April 2014. Background The Company's shares of common stock have been admitted to trading on AIM, since December 2007. Unlike certain other U.S. and foreign exchanges, the AIM Rules for Companies do not require companies to maintain a minimum number of publicly traded shares outstanding at any given time, nor do they require companies to maintain a minimum market capitalization. The Company sought admission to the public market during the early stages of its development by listing shares of its common stock on AIM. In April 2011, the Company completed the initial public offering of its common stock in the United States. At that time, the Company's common stock also became listed on the NYSE MKT (previously known as the NYSE Amex). The Company's Board of Directors unanimously considers the cancellation of admission of its common stock to trading on AIM to be in the best interests of the Company and its stockholders as a whole. Reasons for the Cancellation of Admission to AIM The Company's Board of Directors has identified the following reasons for the proposed cancellation, which it considers to be in the long-term best interests of the Company: The high costs of maintaining the AIM listing. The Company estimates that the annual costs of maintaining a listing on AIM exceed $250,000, and these costs are in addition to the similarly high costs of U.S. securities regulatory and other requirements for maintaining a listing in the United States. Trading on AIM has been limited. The trading of the Company's common stock on AIM has been very limited. A diminishing percentage of the total number of shares of the Company's outstanding common stock is listed on AIM, decreasing from 24% at the end of 2012 to 17% as of 21 February 2014. In addition, based upon information available to the Company, the trading volume of shares of the Company's common stock on AIM averaged less than 1,400 shares per day in 2013, compared to approximately 65,700 shares per day on the
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 27, 2013, Medgenics, Inc., a Delaware corporation (the “Company”), notified Clarence L. “Butch” Dellio, the Company’s Chief Operating Officer, and Marvin R. Garovoy, the Company’s Chief Medical Officer, of the termination of their respective employment agreements, effective December 31, 2013.
Someone has just got 1,342032 shares @ 11655 now that is a strong buy.
Todays news for call for corporate manslaughter charges are a sign for me to sell, and I wont be buying back.
You will need a very long lever to get me out of these shares
Nice Rse but why today